CClinicalTrials.gg
RecruitingNCT07166042Med-RT BGUpdated Oct 3, 2025

Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies

A Phase 3 interventional study of 10-15 minute, Audio-Recorded Guided Mediation Practices in Breast Cancer and Gynecologic Cancer, sponsored by University of Utah. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-03.

Sponsored by University of Utah · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year later.
Phase
Phase 3
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this study is to assess the effect of brief mindfulness-guided meditations during radiation therapy (RT) for patients with anxiety related to RT for breast and gynecological cancers.

02

Conditions studied

  • Breast Cancer
  • Gynecologic Cancer

Browse trials for

03

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's planned enrollment of 34 is below the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

University of Utah is the lead sponsor of 969 studies on the registry; 178 are open to participants now.

Of its 107 completed or terminated interventional studies of FDA-regulated products, 62 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Participant aged ≥ 18 years.
  • Diagnosis of breast or gynelogical cancer.
  • Eligible to receive 15-25 daily radiation therapy treatments for breast or gynelogical cancer.
  • Willing to participate in either the guided meditation or standard of care control arm, regardless of treatment assignment.
  • Karnofsky performance score ≥ 60 or ECOG performance score ≤ 2.
  • Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion criteria

Exclusion Criteria:

  • Active suicidal ideation or active psychotic state in the opinion of the investigator.
  • Patient is receiving deep inspiration breath hold treatment.
  • An unstable illness that, in the opinion of the investigator, would interfere with study treatment.
  • Prior radiation therapy.
  • Inability to understand and/or speak the English language.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Guided Meditation Intervention

    Behavioral: 10-15 minute, Audio-Recorded Guided Mediation Practices

  • No intervention
    Standard of Care

Interventions

  • Behavioral10-15 minute, Audio-Recorded Guided Mediation Practices

    The 5 mindfulness practices, all of which have been validated in prior research. Body Scan practice will consist of how to direct non-judgmental attention to different regions of the body The Mindful Breathing practice will consist of focused attention on the breath and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and body sensations. The Mindfulness of Discomfort practice will consist of instruction in how to "zoom in" to deconstruct discomfort and precisely map each feelings' spatial location, use mindful breathing to "zoom out" and broaden the field of awareness to include neglected sensory elements, and shift attention from unpleasant feelings to neutral/pleasant sensations or experiences. The Savoring practice will consist of instruction in identifying and amplifying pleasant memories. The Loving-Kindness practice will consist of instruction in cultivating feeling of warmth and compassion toward the self and others.

06

What researchers measure

Primary outcomes

  1. Change in acute anxiety in participants receiving mindfulness intervention during RT compared to standard of care control conditions.

    To assess the acute anxiolytic effects of a brief mindfulness intervention during radiation therapy (RT) for patients with anxiety related to RT for breast and gynecological cancers. Acute anxiety during RT will be measured at each treatment visit with an individual item ("How nervous, anxious or on edge do you feel right now?" scored on a 0 (not at all) to 10 (Very much). derived from the Generalized Anxiety Disorder 2-item (GAD-2) scale, measured before and after RT. The change from before to after RT will be averaged over all treatment visits.

    Time frame: 7 weeks

Secondary outcomes

  1. Change in anxiety in everyday life in participants receiving mindfulness intervention during RT compared to standard of care control conditions.

    To assess the distal anxiolytic effects of a brief mindfulness intervention during RT for patients with anxiety related to RT for breast and gynecological cancers. Anxiety in everyday life will be measured using the total score of the Generalized Anxiety Disorder 2-item (GAD-2) scale prior to RT (minimum value 0, maximum value 6, score of 3 or higher considered clinical). This will be measured once a week during RT.

    Time frame: 7 weeks

  2. Change in anxiety during RT and in everyday life as measured by the modified MPoD

    To determine whether the brief mindfulness intervention during RT increases patients' state mindfulness and whether the degree of changes in state mindfulness during RT predict decreases in acute anxiety and anxiety in daily life. Modified Metacognitive Processes of Decentering Scale (MPoD) consists of 4 items scored on a 0-10 scale, "0" meaning "Not at All" and "10" meaning "Very Much".

    Time frame: 7 weeks

  3. Change in self transcendence and the magnitude/degree of increased self transcendence will predict degree of anxiety in the course of daily life as measured by total score of the Nondual Awareness Dimensional Assessment (NADA).

    To determine whether the brief mindfulness intervention during RT increases patients' self transcendence and whether the degree of changes in self-transcendence during RT predict decreases in anxiety in daily life. The NADA will ask patients to rate their feelings 15 minutes before and after treatment on a scale of 0 (not at all) to 10 (very much).

    Time frame: 7 weeks

07

Study locations

1 of 1 sites recruiting
  • Huntsman Cancer Institute at University of Utah
    Salt Lake City, Utah 84112, United States
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07166042
Lead sponsor
University of Utah
Responsible party
Sponsor
First posted
Sep 10, 2025
Start date
Sep 25, 2025
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Oct 3, 2025

Study contacts

Rachel R. Kingford
Contact
rachel.kingsford@hci.utah.edu
801-585-0115
Lindsay Burt, MD
principal investigator · Huntsman Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion